LXEO (Lexeo Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)


LXEO Lexeo Therapeutics Inc LXEO
10 GF Score
Price $4.70
! 3 Warning Signs
View Full Analysis

What is Lexeo Therapeutics OCF Margin %?

Lexeo Therapeutics LXEO -3.69% 10 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates LXEO with a GF Score™ of 10/100. The stock has 3 warning signs investors should review. Among 960 Biotechnology companies, Lexeo Therapeutics ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Lexeo Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-21.14 Mil. Lexeo Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Lexeo Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Lexeo Therapeutics's current OCF Yield % is -26.55%.

The historical rank and industry rank for Lexeo Therapeutics's OCF Margin % or its related term are showing as below:


During the past 6 years, the highest OCF Margin % of Lexeo Therapeutics was -604.83%. The lowest was -8342.51%. And the median was -2666.39%.

LXEO's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Lexeo Therapeutics OCF Margin % Related Terms

Lexeo Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Lexeo Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexeo Therapeutics OCF Margin % Chart

Lexeo Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial -2,666.39 -8,342.51 0.00 0.00 0.00

Lexeo Therapeutics Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LXEO
10GF Score
Lexeo Therapeutics Inc LXEO
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lexeo Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Lexeo Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-98.561/0
= %

Lexeo Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-21.144/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Lexeo Therapeutics (LXEO) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Lexeo Therapeutics and its competitors. According to the industry distribution chart, Lexeo Therapeutics ranks #999999 out of 960 companies in the Biotechnology industry.
Is Lexeo Therapeutics' OCF Margin % too high?
Lexeo Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Lexeo Therapeutics ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lexeo Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Lexeo Therapeutics' OCF Margin % compare to LYEL and XFOR?
According to the Biotechnology industry distribution chart, Lexeo Therapeutics ranks #999999 out of 960 companies for OCF Margin %. This places Lexeo Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Lexeo Therapeutics and its competitors. Lexeo Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexeo Therapeutics stock overvalued right now?
Lexeo Therapeutics (LXEO) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Lexeo Therapeutics' overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Lexeo Therapeutics (LXEO), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lexeo Therapeutics Business Description

Address 345 Park Avenue South, Floor 6, New York, NY, USA, 10010
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
10GF Score

Get the complete analysis for LXEO

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.70
Price